Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Phase I trials begin for Fabry's disease

Jan. 24, 1997

Muse licensed to Janssen for certain markets

Jan. 24, 1997

GelTex reports CholestaGel phase II data

Jan. 24, 1997

Positive phase II results reported for platelet substitute

Jan. 24, 1997

Additional beneficial lipid-modifying effects of FCP-3P1 reported

Jan. 24, 1997

Cerebrus discovers role of gene in obesity

Jan. 24, 1997

Inhibitors of alpha-amylase disclosed by Japanese researchers

Jan. 23, 1997

ACAT inhibitors from Takeda

Jan. 23, 1997

NESP enters clinical trials

Jan. 22, 1997

Ergo readying first NDA submission

Jan. 22, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...